Eli Net Receivables from 2010 to 2024

LLY Stock  USD 777.96  0.22  0.03%   
Eli Lilly Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables is likely to outpace its year average in 2024. During the period from 2010 to 2024, Eli Lilly Net Receivables regression line of annual values had r-squared of  0.86 and arithmetic mean of  5,927,300,667. View All Fundamentals
 
Net Receivables  
First Reported
1985-12-31
Previous Quarter
10.4 B
Current Value
11.3 B
Quarterly Volatility
2.2 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli main balance sheet or income statement drivers, such as Depreciation And Amortization of 994.5 M, Interest Expense of 327.9 M or Total Revenue of 35.8 B, as well as many exotic indicators such as Short Term Coverage Ratios of 0.58, Price Earnings Ratio of 105 or Price To Sales Ratio of 16.15. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
  
This module can also supplement Eli Lilly's financial leverage analysis and stock options assessment as well as various Eli Lilly Technical models . Check out the analysis of Eli Lilly Correlation against competitors.

Latest Eli Lilly's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Eli Lilly And over the last few years. It is Eli Lilly's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Eli Net Receivables Regression Statistics

Arithmetic Mean5,927,300,667
Geometric Mean5,062,591,945
Coefficient Of Variation50.57
Mean Deviation2,295,707,556
Median5,262,200,000
Standard Deviation2,997,183,896
Sample Variance8983111.3T
Range11.2B
R-Value0.93
Mean Square Error1336508.7T
R-Squared0.86
Slope622,176,321
Total Sum of Squares125763558.3T

Eli Net Receivables History

202411.9 B
202311.3 B
20228.6 B
20218.1 B
20206.9 B
20195.5 B
20185.8 B

About Eli Lilly Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Eli Lilly income statement, its balance sheet, and the statement of cash flows. Eli Lilly investors use historical funamental indicators, such as Eli Lilly's Net Receivables, to determine how well the company is positioned to perform in the future. Although Eli Lilly investors may use each financial statement separately, they are all related. The changes in Eli Lilly's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eli Lilly's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eli Lilly Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Net Receivables11.3 B11.9 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Eli Lilly And offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out the analysis of Eli Lilly Correlation against competitors.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.13
Dividend Share
4.52
Earnings Share
5.81
Revenue Per Share
37.908
Quarterly Revenue Growth
0.281
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.